Evidence map›Paper›PMID 36365112›Full record

ReviewPharmaceutics2022

Advanced Drug Delivery Platforms for the Treatment of Oral Pathogens.

Seyed Ebrahim Alavi, Aun Raza, Max Gholami, Michael Giles, Rayan Al-Sammak, Ali Ibrahim, Hasan Ebrahimi Shahmabadi, Lavanya A Sharma

Open access · goldAbstract readReview
In one paragraph

Review in Pharmaceutics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 1 pooled it
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Photocatalytic TiORSC advances · 2025
    Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Review
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 3 countries.

Seyed Ebrahim AlaviSchool of Medicine and Dentistry, Griffith University, Gold Coast, QLD 4215, Australia.ORCID 0000-0003-4009-4921
Aun RazaSchool of Pharmacy, Jiangsu University, Zhenjiang 212013, China.
Max GholamiSchool of Medicine and Dentistry, Griffith University, Gold Coast, QLD 4215, Australia.ORCID 0000-0003-3854-6773
Michael GilesSchool of Medicine and Dentistry, Griffith University, Gold Coast, QLD 4215, Australia.
Rayan Al-SammakSchool of Medicine and Dentistry, Griffith University, Gold Coast, QLD 4215, Australia.
Ali IbrahimSchool of Medicine and Dentistry, Griffith University, Gold Coast, QLD 4215, Australia.
Hasan Ebrahimi ShahmabadiImmunology of Infectious Diseases Research Center, Research Institute of Basic Medical Sciences, Rafsanjan University of Medical Sciences, Rafsanjan 7717933777, Iran.ORCID 0000-0001-5222-3829
Lavanya A SharmaSchool of Medicine and Dentistry, Griffith University, Gold Coast, QLD 4215, Australia.
Griffith University · AUJiangsu University · CNRafsanjan University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The oral cavity is a complex ecosystem accommodating various microorganisms (e.g., bacteria and fungi). Various factors, such as diet change and poor oral hygiene, can change the composition of oral microbiota, resulting in the dysbiosis of the oral micro-environment and the emergence of pathogenic microorganisms, and consequently, oral infectious diseases. Systemic administration is frequently used for drug delivery in the treatment of diseases and is associated with the problems, such as drug resistance and dysbiosis. To overcome these challenges, oral drug delivery systems (DDS) have received considerable attention. In this literature review, the related articles are identified, and their findings, in terms of current therapeutic challenges and the applications of DDSs, especially nanoscopic DDSs, for the treatment of oral infectious diseases are highlighted. DDSs are also discussed in terms of structures and therapeutic agents (e.g., antibiotics, antifungals, antiviral, and ions) that they deliver. In addition, strategies (e.g., theranostics, hydrogel, microparticle, strips/fibers, and pH-sensitive nanoparticles), which can improve the treatment outcome of these diseases, are highlighted.

Indexed as

antibacterial agentsdrug resistanceinfection controlmicrobiologyoral pathology

Identifiers

PMID36365112
PMCPMC9692332
OpenAlexW4307552015

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.